Citação norma APA

Fishman, M. (2019). Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer (“KEYNOTE 045”). Transl Androl Urol.

Citação norma Chicago

Fishman, Mayer. "Commentary: 2-year Follow Up of Pembrolizumab As Second-line Therapy for Advanced Urothelial Cancer (“KEYNOTE 045”)." Transl Androl Urol 2019.

Citação norma MLA

Fishman, Mayer. "Commentary: 2-year Follow Up of Pembrolizumab As Second-line Therapy for Advanced Urothelial Cancer (“KEYNOTE 045”)." Transl Androl Urol 2019.

Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.